Geron
Foster City, California, United States · Biotechnology, Health Care, research · 405 employees
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clin
Funding history
- Funding Round — $375.0M — Nov 2024
Recent signals
- Apr 16, 2026: Geron Appoints Timothy Williams as Chief Legal Officer
- Apr 15, 2026: Geron Appoints Timothy Williams as Executive Vice President, Chief Legal Officer
- Jan 05, 2026: SEC 8-K (1.01): On January 5, 2026, Geron Corporation entered into a first amendment to a loan agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, amending the terms of a prior loan agreement made on November 1, 2024. The amended loan agreement enables a senior secured term loan facility of up to $250.0 million, split into three committed tranches. The most significant tranche, Tranche A, amounts to $125.0 million. This amendment reflects a strategic move for Geron Corporation to bolster its financial flexibility and support ongoing operational objectives.
- Oct 13, 2025: Geron Corporation Appoints Ahmed ElNawawi as Chief Commercial Officer
- Oct 10, 2025: SEC 8-K (5.02): On October 10, 2025, Gaurav Aggarwal, M.D., announced his immediate resignation from the Board of Directors of Geron Corporation due to professional obligations, which was confirmed to be unrelated to any disagreements with the company. Additionally, V. Bryan Lawlis, Ph.D., notified the Board of his decision not to seek re-election at the 2026 Annual Meeting of Stockholders while he will remain a director until the end of his current term. These departures reflect changes in the board composition, which may impact the company's governance and strategic direction moving forward.
- Aug 06, 2025: Geron Corporation Appoints Harout Semerjian as President and CEO
- Dec 13, 2024: Launched Geron Corporation announces positive CHMP opinion for RYTELO, aimed at treating adults with transfusion-dependent anemia due to lower-risk MDS.
- Nov 07, 2024: Raised $375.0M
See plans & pricing → Track Geron’s funding, hiring, and signals — with verified contacts — on Fundz.